doses semaglutide Dosing Ozempic® Pen Dosing | Ozempic®

Impact of treatment on quality of life outcome assessments

Lab work, symptoms, lifestyle, and health history all play a role in determining whether either, or both, are appropriate

then glutathione sounds a lot like a silver bullet

And that's where we're headed today

GHRH/GHS-R Dual Secretagogue Blend This research blend combines CJC-1295 without DAC (Modified GRF 1-29), a stabilized GHRH analog, with Ipamorelin, a selective GHS-R agonist

Key Findings: Large human studies across multiple countries have not found increased thyroid cancer rates in GLP-1 users The FDA warning applies to medullary thyroid carcinoma (MTC)only 3-4% of all thyroid cancers The warning exists because rodents developed C-cell tumors, but humans and rodents differ biologically Some studies show associations, but these are explained by detection bias (more monitoring = finding pre-existing nodules) The Clayman Thyroid Center (2,000+ thyroid cancer patients/year) has not seen an MTC pattern linked to GLP-1 use (or for that matter any other thyroid malignancy) Clinical Recommendations: Patients with MTC history or MEN2 should not take GLP-1 receptor agonists Patients with common thyroid cancers (papillary, follicular, Hrthle cell) should not assume GLP-1 caused them or will have an effect upon them Decisions should be individualized, weighing metabolic benefits against theoretical concerns GLP-1 therapy does not require additional thyroid monitoring Quick Reference for Clinicians Understanding the Question What Medications Are We Discussing